However, there are rarer mutations which also contribute to tumor heterogeneity that can also be attacked, as G719S and L851Q mutations in EGFR. Moreover, in recent years, liquid biopsy has been introduced as a tool of high potential for obtaining samples noninvasively of cancer patients in order to carry out this genetic diagnosis. This evidence concerns the gene EGFR and cancer.